Back to Search Start Over

Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study.

Authors :
Tiziano, Francesco D
Lomastro, Rosa
Di Pietro, Lorena
Barbara Pasanisi, Maria
Fiori, Stefania
Angelozzi, Carla
Abiusi, Emanuela
Angelini, Corrado
SorarĂ¹, Gianni
Gaiani, Alessandra
Mongini, Tiziana
Vercelli, Liliana
Vasco, Gessica
Vita, Giuseppe
Luca Vita, Gian
Messina, Sonia
Politano, Luisa
Passamano, Luigia
Di Gregorio, Grazia
Montomoli, Cristina
Source :
European Journal of Human Genetics. Jun2013, Vol. 21 Issue 6, p630-636. 7p. 1 Chart, 4 Graphs.
Publication Year :
2013

Abstract

Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations of the SMN1 gene. Based on severity, three forms of SMA are recognized (types I-III). All patients usually have 2-4 copies of a highly homologous gene (SMN2), which produces insufficient levels of functional survival motor neuron (SMN) protein due to the alternative splicing of exon 7. The availability of potential candidates to the treatment of SMA has raised a number of issues, including the availability of biomarkers. This study was aimed at evaluating whether the quantification of SMN2 products in peripheral blood is a suitable biomarker for SMA. Forty-five adult type III patients were evaluated by Manual Muscle Testing, North Star Ambulatory Assessment scale, 6-min walk test, myometry, forced vital capacity, and dual X-ray absorptiometry. Molecular assessments included SMN2 copy number, levels of full-length SMN2 (SMN2-fl) transcripts and those lacking exon 7 and SMN protein. Clinical outcome measures strongly correlated to each other. Lean body mass correlated inversely with years from diagnosis and with several aspects of motor performance. SMN2 copy number and SMN protein levels were not associated with motor performance or transcript levels. SMN2-fl levels correlated with motor performance in ambulant patients. Our results indicate that SMN2-fl levels correlate with motor performance only in patients preserving higher levels of motor function, whereas motor performance was strongly influenced by disease duration and lean body mass. If not taken into account, the confounding effect of disease duration may impair the identification of potential SMA biomarkers. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10184813
Volume :
21
Issue :
6
Database :
Academic Search Index
Journal :
European Journal of Human Genetics
Publication Type :
Academic Journal
Accession number :
87598055
Full Text :
https://doi.org/10.1038/ejhg.2012.233